| P1. Advancing Gene Therapies for Inherited Hematopoietic Disorders | | | | |
| P2. Induced Pluripotent Stem Cell (iPSC) derived mesenchymal stroma cell therapy to recover damaged donor lungs for transplantation | | | | |
| P3. Modeling Inhibitory Neuron Dysfunction in Psychiatric Disease for Therapeutic Discovery | | | | |
| P4. Harnessing Cellular Reprogramming to Generate Tumor‑Reactive T Cells | | | | |
| P5. LUNG – REBOOT: Bioengineering a biomaterial-guided ATMP to reconstruct distal lung tissue | | | | |
| P6. Inflammation‑Regulated Gene Therapy for Neurological Disorders | | | | |
| P7. Understanding Transcriptional Regulation for the Generation of Dopamine Neurons: A Perturb‑Seq Approach for Stem Cell Therapy in Parkinson's Disease | | | | |
| P8. Function focus in development of Chimeric Antigen Receptor (CAR)‑based therapy | | | | |
| P9. Reconditioning Discarded Donor Lungs with Next‑Generation Engineered iMSCs: A Translational ATMP Platform for Lung Transplantation | | | | |
| P10. Cell‑Selective Gene Delivery to Restore Vascular Smooth Muscle Function in Aging Vessels | | | | |
| P11. Transplantation of gene‑repaired hematopoietic stem cells as novel treatment for myelofibrosis | | | | |
| P12. Brain repair after stroke by new reprogrammed neurons and oligodendrocytes | | | | |
| P13. iPSC-derived and CAR-enhanced natural killer cells as an advanced off-the-shelf technology to treat autoimmune diseases | | | | |
| P14. Novel gene therapy approaches for Diamond-Blackfan Anemia | | | | |
| P15. Designer Macrophages: Modular, Target-Responsive iPSC-Derived Macrophages for Neurodegenerative Disorders | | | | |
| P16. Development of novel CAR-T and CAR-NK cells against cancer | | | | |
| P17. Understanding clonal dynamics in gene therapy trials | | | | |
| P18. Beta-cell destruction in type 1 diabetes: when sweetness fails | | | | |
| P19. Human iThy-organoids restore T cell immunity in thymus-deficient patients | | | | |
| P20. Repair-Independent Gene Integration in Patient-Derived Human HSPCs for Immune Correction of ZIP7 Deficiency | | | | |
| P21. Engineering Lentiviral Vectors for Precise Gene Expression to Improve Safety of Hematopoietic Stem Cell Gene Therapy | | | | |